DDInter1400 DDInter1752
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Drug-resistant bacteria, such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and penicillin-resistant _Streptococcus penumoniae_, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than [linezolid].[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.
Pazopanib {u} (Compound) treats {v} (Disease) kidney cancer
Pazopanib {u} (Compound) binds {v} (Gene) PIP4K2C
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
Pazopanib {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C8 Inhibitors
Pazopanib {u} (Compound) downregulates {v} (Gene) MEST
Pazopanib {u} (Compound) causes {v} (Side Effect) Rhinorrhoea
Pazopanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Pazopanib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perphenazine
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romosozumab
Pazopanib (Compound) treats kidney cancer (Disease)
Pazopanib (Compound) binds PIP4K2C (Gene)
Pazopanib (Compound) upregulates SRC (Gene)
Pazopanib (Compound) is included by Cytochrome P450 2C8 Inhibitors (Pharmacologic Class)
Pazopanib (Compound) downregulates MEST (Gene)
Pazopanib (Compound) causes Rhinorrhoea (Side Effect)
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Doravirine
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab